Table 3.
Association between select PCB congeners and PCB groupings and risk of metastatic prostate cancer in the Janus study.
| Metabolite | Continuous | Q1 | Q2 vs. Q1 | Q3 vs. Q1 | Q4 vs. Q1 | p-Trendc | |||
|---|---|---|---|---|---|---|---|---|---|
| ORa,b (95% CI) | Ca/Co | Ca/Co | ORb (95% CI) | Ca/Co | ORb (95% CI) | Ca/Co | ORb (95% CI) | ||
| Selected PCB congenerd | |||||||||
| 44 | 0.74 (0.56, 0.97) | 48/79 | 38/78 | 0.74 (0.41, 1.33) | 39/79 | 0.67 (0.35, 1.28) | 25/78 | 0.39 (0.17, 0.86) | 0.02 |
| 101 | 0.79 (0.57, 1.09) | 48/79 | 28/78 | 0.52 (0.29, 0.95) | 45/79 | 0.84 (0.47, 1.49) | 29/78 | 0.51 (0.25, 1.03) | 0.16 |
| 153 | 0.92 (0.59, 1.43) | 35/79 | 39/78 | 1.01 (0.57, 1.78) | 42/79 | 1.04 (0.58, 1.85) | 34/78 | 0.83 (0.44, 1.56) | 0.56 |
| 180 | 0.64 (0.36, 1.13) | 31/77 | 43/79 | 1.19 (0.66, 2.17) | 48/80 | 1.38 (0.75, 2.54) | 28/78 | 0.71 (0.36, 1.38) | 0.25 |
| 189 | 0.90 (0.73, 1.12) | 47/78 | 41/79 | 0.93 (0.43, 2.00) | 33/79 | 0.72 (0.34, 1.54) | 29/78 | 0.64 (0.30, 1.37) | 0.18 |
| Total PCBse | 0.99 (0.98, 1.01) | 38/78 | 38/79 | 0.82 (0.46, 1.45) | 34/77 | 0.82 (0.45, 1.50) | 40/80 | 0.92 (0.50, 1.68) | 0.88 |
| Degree of chlorinationf | |||||||||
| Low | 0.95 (0.89, 1.01) | 44/78 | 37/79 | 0.58 (0.31, 1.09) | 34/78 | 0.58 (0.29, 1.17) | 35/79 | 0.59 (0.26, 1.32) | 0.44 |
| Moderate | 1.00 (0.98, 1.02) | 33/76 | 38/80 | 0.92 (0.51, 1.65) | 44/80 | 1.22 (0.68, 2.21) | 35/78 | 0.94 (0.51, 1.73) | 0.99 |
| High | 0.99 (0.91, 1.08) | 38/78 | 35/79 | 1.00 (0.57, 1.77) | 45/79 | 1.18 (0.67, 2.06) | 32/78 | 0.89 (0.48, 1.64) | 0.73 |
| Wolff groupg | |||||||||
| 1 | 0.95 (0.88, 1.02) | 42/76 | 39/81 | 0.88 (0.49, 1.56) | 41/78 | 0.97 (0.54, 1.72) | 28/79 | 0.63 (0.32, 1.23) | 0.19 |
| 1A | 0.91 (0.81, 1.01) | 48/78 | 36/79 | 0.67 (0.37, 1.19) | 40/79 | 0.62 (0.33, 1.18) | 26/78 | 0.39 (0.18, 0.85) | 0.03 |
| 1B | 0.97 (0.86, 1.10) | 38/78 | 38/79 | 0.92 (0.52, 1.63) | 39/78 | 1.06 (0.60, 1.90) | 35/79 | 0.88 (0.48, 1.62) | 0.77 |
| 2 | 0.99 (0.93, 1.05) | 38/77 | 35/80 | 0.80 (0.44, 1.43) | 41/78 | 1.09 (0.62, 1.91) | 36/79 | 0.85 (0.45, 1.60) | 0.85 |
| 2A | 0.99 (0.90, 1.09) | 40/78 | 38/78 | 0.84 (0.47, 1.50) | 35/80 | 0.89 (0.50, 1.60) | 37/78 | 0.91 (0.48, 1.72) | 0.88 |
| 2B | 0.98 (0.87, 1.10) | 33/78 | 42/78 | 1.14 (0.64, 2.03) | 43/79 | 1.23 (0.69, 2.19) | 32/79 | 0.85 (0.46, 1.60) | 0.60 |
| 3 | 0.96 (0.87, 1.06) | 34/78 | 40/79 | 1.06 (0.60, 1.86) | 43/79 | 1.13 (0.63, 2.05) | 33/78 | 0.84 (0.45, 1.57) | 0.57 |
| Abbreviations: Ca/Co, cases/controls; OR, odds ratio; PCB, polychlorinated biphenyl; Q, quartile. aPer unit increase in natural log–transformed ng/g lipid. bAdjusted for county, age at collection, and date at collection. cTrend of median values across quartiles. dEstimates for the remaining PCBs are provided in Supplemental Material, Table S3. eSum of all congeners included in the analysis. fLow: PCBs 11, 18, 28, 44, 49, 52, 66, and 74; moderate: PCBs 99, 105, 110, 118, 128, 138, 146, 153, 156, 157, 167, 170, 172, 177, 178, 180, 183, 187, and 189; high: PCBs 194, 195, 196, 201, 206, and 209. gWolff 1A: PCBs 44, 49, and 52; Wolff 1B: PCBs 177, 187, and 201; Wolff 2A: PCBs 66, 74, 105, 118, 156, and 167; Wolff 2B: PCBs 128, 138, and 170; Wolff 3: PCBs 99, 153, 180, 183, and 196. | |||||||||